Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Zi-Hui WangNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.ORCID https://orcid.org/0000-0003-1712-2293
Chang XuNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.ORCID https://orcid.org/0000-0002-7697-7833
Yao-Yao MaNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.ORCID https://orcid.org/0009-0005-2258-6975
Wei-Xuan XueNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
Hao-Yuan WangNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.ORCID https://orcid.org/0009-0000-6941-9983
Lin-Yao FanNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.ORCID https://orcid.org/0009-0005-1848-7026
Chen-Yu ZhangNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
Liang LiNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
Xiao-Yang ZhangNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
Jing-Ning ZhuNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
Qi-Peng ZhangNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.ORCID https://orcid.org/0000-0002-3697-0194
Funding
Fundamental Research Funds for the Central Universities 020814380077Fundamental Research Funds for the Central Universities 020814380119Fundamental Research Funds for the Central Universities 020814380164Ministry of Science and Technology of the People's Republic of China 2021ZD0202805Nanjing University Integrated Research Platform of the Ministry of Education of China TopTalentsProgram2024300475National Natural Science Foundation of China 32030044National Natural Science Foundation of China 32171012National Natural Science Foundation of China 32270998National Natural Science Foundation of China 32471037National Science and Technology Major Project 2023ZD0507200The Natural Science Foundation of Jiangsu Province of China BK20240168The State Key Laboratory of Pharmaceutical Biotechnology of China LNSN-202402
6 · The paper itself
Abstract
Accumulating evidence has identified disrupted oxytocin signaling in both autistic patients and animal models of autism. Nevertheless, the specific timing of the impact of oxytocin on social behavior has remained unclear. Using mouse strains from oxytocin-Cre mice crossed with Cre-dependent chemogenetic mice, oxytocinergic neuronal activity is selectivity manipulated during the early or late postnatal stages and revealed, for the first time, that the suppression of oxytocinergic neurons in the early rather than late postnatal stage led to the emergence of autistic-like behaviors. Notably, significantly reduced oxytocin levels are identified specifically during the early postnatal stage in both valproic acid (VPA)-exposed and Fmr1-KO mouse brains, along with an impairment of the GABA reversal potential and downregulation of the Na
Indexed as
Autistic Disordergamma-Aminobutyric AcidOxytocinSolute Carrier Family 12, Member 2AnimalsBehavior, AnimalDisease Models, AnimalMaleMiceMice, KnockoutNeuronsSocial BehaviorValproic Acidgamma-Aminobutyric AcidOxytocinSlc12a2 protein, mouseSolute Carrier Family 12, Member 2Valproic Acidautismearly postnatal stageGABA reverse potentialNKCC1oxytocin
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Oxytocin Improves Autistic Behaviors by Positively Shifting GABA Reversal Potential via NKCC1 in Early-Postnatal-Stage. · full record | OpenQuestion